Add to ORKG<p>Supplemental material, Table S1 for Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis by Jingjing Lv, Dongmei Zhou, Yan Wang, Jingxia Zhao, Zhaoxia Chen, Jinchao Zhang, Tingting Di, Jing Hu, Bo Li, Ping Li and Feng Huang in Molecular Pain</p
<p>Supplemental material for Comparison of the efficacy and safety of non-steroidal anti-inflammator...
Supplemental material, Supplement_1_-_June_8_-_JCMS for Satisfaction and Awareness of Systemic Psori...
<p><b><i>Aim:</i></b> Psoriasis is an inflammatory skin disease, and approximately one quarter of i...
Supplemental material, Supplement_Table_S1 for Effectiveness and safety of secukinumab for psoriasis...
Supplemental material, Supplement_Table_S2 for Effectiveness and safety of secukinumab for psoriasis...
Supplemental material, Supplement_Table_S3 for Effectiveness and safety of secukinumab for psoriasis...
Supplemental material, Supplement_Table_S4 for Effectiveness and safety of secukinumab for psoriasis...
Supplemental material, Supplemental__Figure_1 for Effectiveness and safety of secukinumab for psoria...
<p>Supplemental material, Table_1 for A mixed treatment comparison on efficacy and safety of treatme...
Supplemental Table 1 for "Real-world trends in biologic, oral systemic and phototherapy in United St...
Supplemental material for the manuscript, "Comparative Safety and Benefit-Risk Profile of Biologics ...
Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...
Summary of results at Week 24 from included trials for the overall population. (DOCX 40Â kb
Purpose: This network meta-analysis was aimed to enhance the corresponding evidence with respect to ...
Summary of results at Week 24 from included trials among biologic-naĂŻve population. (DOCX 36Â kb
<p>Supplemental material for Comparison of the efficacy and safety of non-steroidal anti-inflammator...
Supplemental material, Supplement_1_-_June_8_-_JCMS for Satisfaction and Awareness of Systemic Psori...
<p><b><i>Aim:</i></b> Psoriasis is an inflammatory skin disease, and approximately one quarter of i...
Supplemental material, Supplement_Table_S1 for Effectiveness and safety of secukinumab for psoriasis...
Supplemental material, Supplement_Table_S2 for Effectiveness and safety of secukinumab for psoriasis...
Supplemental material, Supplement_Table_S3 for Effectiveness and safety of secukinumab for psoriasis...
Supplemental material, Supplement_Table_S4 for Effectiveness and safety of secukinumab for psoriasis...
Supplemental material, Supplemental__Figure_1 for Effectiveness and safety of secukinumab for psoria...
<p>Supplemental material, Table_1 for A mixed treatment comparison on efficacy and safety of treatme...
Supplemental Table 1 for "Real-world trends in biologic, oral systemic and phototherapy in United St...
Supplemental material for the manuscript, "Comparative Safety and Benefit-Risk Profile of Biologics ...
Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...
Summary of results at Week 24 from included trials for the overall population. (DOCX 40Â kb
Purpose: This network meta-analysis was aimed to enhance the corresponding evidence with respect to ...
Summary of results at Week 24 from included trials among biologic-naĂŻve population. (DOCX 36Â kb
<p>Supplemental material for Comparison of the efficacy and safety of non-steroidal anti-inflammator...
Supplemental material, Supplement_1_-_June_8_-_JCMS for Satisfaction and Awareness of Systemic Psori...
<p><b><i>Aim:</i></b> Psoriasis is an inflammatory skin disease, and approximately one quarter of i...